arry-371797
Small moleculeexperimental
Clinical trial activity
10 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
7
Phase 3
1
Phase 4
0
Earliest trial started Oct 1, 2007 (NCT00542035)
Timeline
Indications
Mechanism of action
- MAP kinase p38 alphaINHIBITOR
MAPK14 inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
CC(C)Cn1ncc2cc(Oc3ccc(F)cc3F)c(C(=O)NCCN(C)C)cc21- Mol. weight
- 416.47 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL1088750 ↗
Also known as
- arry-371797
- arry-371797
- arry-371797
- arry-371797
- arry-797
- arry-797
- arry-797
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05286281 | Phase 1 | Mar 31, 2022 | Pfizer |
| NCT03439514 | Phase 3 | Mar 12, 2018 | Array BioPharma |
| NCT02351856 | Phase 2 | Feb 1, 2015 | Array BioPharma |
| NCT02057341 | Phase 2 | Feb 1, 2014 | Array BioPharma |
| NCT01366014 | Phase 2 | Jun 1, 2011 | Array BioPharma |
| NCT00811499 | Phase 2 | Dec 1, 2008 | Array BioPharma |
| NCT00790049 | Phase 1 | Oct 1, 2008 | Array BioPharma |
| NCT00729209 | Phase 1 | Jul 1, 2008 | Array BioPharma |
| NCT00663767 | Phase 2 | Apr 1, 2008 | Array BioPharma |
| NCT00542035 | Phase 2 | Oct 1, 2007 | Array BioPharma |
Showing 10 of 10 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Array BioPharma | For profit | 9 | 9 | 3 | 2007 |
| Pfizer | For profit | 1 | 1 | 1 | 2022 |
2 organizations
Page 1 / 1